Business growth

Halozyme and ViiV Healthcare have entered into an agreement to develop Enhanze's high-volume subcutaneous injection technology for the treatment of HIV. As part of the deal, ViiV will pay $40 million for an exclusive license and $175 million in installments when certain development milestones are reached. The first experiments with Enhanze will begin by the end of 2021.